Skip to main content
. Author manuscript; available in PMC: 2021 Sep 1.
Published in final edited form as: Brachytherapy. 2020 Jun 20;19(5):679–684. doi: 10.1016/j.brachy.2020.05.002

Table 2.

Baseline Clinical/Tumor Characteristics

n = 204
Median age (years) 64.2 (IQR 11.9)
Histology
 IDC 135 (66.2%)
 DCIS 54 (26.5%)
 ILC 11 (5.4%)
 Other 4 (2.0%)
Laterality
 Left 86 (42.2%)
 Right 117 (57.4%)
Receptor Status
 ER+ 195 (95.6%)
 PR+ 145 (71.1%)
 *HER2+ 10 (7.4%)
*ER− PR− HER2− 4 (3.0%)
Postoperative
 Close or positive margins 13 (6.4%)
 Surgical re-excision 7 (3.4%)
 WBI after re-excision 7 (3.4%)
*

HER2 receptor status routinely only checked for patients with IDC. Positivity rate reported here is among patients with a primary diagnosis of IDC.